15th Nov 2013 17:08
LONDON (Alliance News) - Worldwide Healthcare Trust PLC Friday said it significantly outperformed its benchmark over the half year, citing the performance of portfolio companies in medical devices, emerging biotechnology, large-capitalisation biotechnology, generic drug makers, and large-capitalisation pharmaceuticals.
The company's net asset value total return was 8.8% in the six months to September 30, significantly outperforming the benchmark's return of 2.8%. The principal contributors to net asset value performance came from holdings in MAKO Surgical, Incyte and Gilead Sciences.
"So far 2013 has been a good year for the healthcare sector, it having outperformed the broader market by some margin. Our investment manager believes that prospects for the sector are bright with valuations remaining attractive despite the uncertainty surrounding healthcare
in the US," Martin Smith, chairman, said in a statement.
The benchmark is the MSCI World Health Care Index on a net total return, sterling adjusted basis.
The trust's shares Friday closed at 1,184.04 pence, down 0.3%.
By Samuel Agini; [email protected]; @samuelagini
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Worldwide Healthcare Trust